Novavax Total Liab from 2010 to 2024

NVAX Stock  USD 9.11  0.09  1.00%   
Novavax Total Liabilities yearly trend continues to be fairly stable with very little volatility. Total Liabilities is likely to outpace its year average in 2024. Total Liabilities is the total amount of all liabilities that Novavax has, including both short-term and long-term liabilities. View All Fundamentals
 
Total Liabilities  
First Reported
1996-03-31
Previous Quarter
2.3 B
Current Value
2.2 B
Quarterly Volatility
820.7 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Novavax financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novavax's main balance sheet or income statement drivers, such as Depreciation And Amortization of 43.3 M, Interest Expense of 15.1 M or Selling General Administrative of 499.1 M, as well as many indicators such as Price To Sales Ratio of 0.47, Dividend Yield of 0.0066 or Days Sales Outstanding of 82.31. Novavax financial statements analysis is a perfect complement when working with Novavax Valuation or Volatility modules.
  
Check out the analysis of Novavax Correlation against competitors.
For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Latest Novavax's Total Liab Growth Pattern

Below is the plot of the Total Liab of Novavax over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Novavax's Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novavax's overall financial position and show how it may be relating to other accounts over time.
Total Liab10 Years Trend
Slightly volatile
   Total Liab   
       Timeline  

Novavax Total Liab Regression Statistics

Arithmetic Mean911,856,990
Geometric Mean197,919,535
Coefficient Of Variation128.70
Mean Deviation982,896,387
Median375,913,000
Standard Deviation1,173,598,676
Sample Variance1377333.9T
Range2.9B
R-Value0.85
Mean Square Error404739.1T
R-Squared0.73
Significance0.000054
Slope223,774,968
Total Sum of Squares19282673.9T

Novavax Total Liab History

20242.6 B
20232.5 B
20222.9 B
20212.9 B
2020955.3 M
2019359 M
2018375.9 M

About Novavax Financial Statements

Novavax investors use historical fundamental indicators, such as Novavax's Total Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Novavax. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Liabilities2.5 B2.6 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Novavax Stock Analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.